Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.45 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8145007 | 0.87 | L3MBTL3 (0.41) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL6975017 | 0.85 | CHRNB2 (0.52) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL26496894 | 0.84 | L3MBTL3 (0.41) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL27960069 | 0.83 | CA2 (0.48) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL20808277 | 0.82 | L3MBTL3 (0.45) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNB3 | |
| SCHEMBL13462187 | 0.82 | CHRNB2 (0.43) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL21039950 | 0.82 | CHRNB2 (0.43) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL4541398 | 0.82 | CHRNB2 (0.41) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL18711669 | 0.81 | CHRNB2 (0.45) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL26496895 | 0.81 | L3MBTL3 (0.44) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | AMGEN INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200171043-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190201412-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2019-07-04 | — | — | US | disclosed |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-8987247-B2 | Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-24 | — | — | US | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-28 | — | — | US | disclosed |
| US-8362000-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-29 | — | — | US | disclosed |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015171-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | disclosed |
| US-20100331300-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331299-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-30 | — | — | US | disclosed |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324013-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324012-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324011-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201412-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CHRNB2 4847/4885CHRNA3 4868/4885CHRNA4 4879/4885 |
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | CHRNB2 4847/4885CHRNA3 4868/4885CHRNA4 4879/4885 |
| US-20100324011-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CHRNB2 3880/4885CHRNA3 4176/4885CHRNA4 4538/4885 |
| US-20110015171-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CHRNB2 3880/4885CHRNA3 4176/4885CHRNA4 4538/4885 |
| US-20100324013-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CHRNB2 3880/4885CHRNA3 4176/4885CHRNA4 4538/4885 |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CHRNB2 3880/4885CHRNA3 4176/4885CHRNA4 4538/4885 |
| US-20100331299-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CHRNB2 3880/4885CHRNA3 4176/4885CHRNA4 4538/4885 |
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CHRNB2 3880/4885CHRNA3 4176/4885CHRNA4 4538/4885 |
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | CHRNB2 4847/4885CHRNA3 4868/4885CHRNA4 4879/4885 |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | CHRNB2 4847/4885CHRNA3 4868/4885CHRNA4 4879/4885 |
| US-20100324012-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CHRNB2 3880/4885CHRNA3 4176/4885CHRNA4 4538/4885 |
| US-20100331300-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CHRNB2 3880/4885CHRNA3 4176/4885CHRNA4 4538/4885 |
| US-20200171043-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CHRNB2 4847/4885CHRNA3 4868/4885CHRNA4 4879/4885 |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | MCL1, BCL9, BCL2L1 | CHRNB2 4846/4885CHRNA3 4866/4885CHRNA4 4879/4885 |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | CHRNB2 3880/4885CHRNA3 4176/4885CHRNA4 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.